|Elimination half-life||7.2 days|
|Chemical and physical data|
|Molar mass||143801.3 g/mol|
|(what is this?)|
Basiliximab (trade name Simulect) is a chimeric mouse-human monoclonal antibody to the α chain (CD25) of the IL-2 receptor of T cells. It is used to prevent rejection in organ transplantation, especially in kidney transplants. It is a Novartis product and was approved by the Food and Drug Administration (FDA) in 1998.
Basiliximab is an immunosuppressant agent used to prevent immediate transplant rejection in people who are receiving kidney transplants, in combination with other agents. It has been reported that some cases of lichen planus have been successfully treated with basiliximab as an alternative therapy to ciclosporin. No short-term side effects have been reported.
Mechanism of action
Basiliximab competes with IL-2 to bind to the alpha chain subunit of the IL2 receptor on the surface of the activated T lymphocytes and thus prevents the receptor from signaling. This prevents T cells from replicating and also from activating B cells, which are responsible for the production of antibodies, which would bind to the transplanted organ and stimulate an immune response against the transplant.
References and notes
- MedlinePlus. Last Revised - June 15, 2012 Basiliximab Injection
- A.D. Katsambas, T.M. Lotti European handbook of dermatological treatments 2nd edition, 2003, page 291, ISBN 3-540-00878-0
- Hardinger KL, Brennan DC, Klein CL. Selection of induction therapy in kidney transplantation. Transpl Int. 2013 Jul;26(7):662-72. PMID 23279211
- Basiliximab label
- Waldman, Thomas A. (2003). Immunotherapy: past, present and future. Nature Medicine 9, 269-277.